Login to Your Account



Avanir Selling FazaClo, $52M To Push Ongoing Zenvia Work

By Jennifer Boggs


Thursday, July 5, 2007
Avanir Pharmaceuticals Inc. expects to pull in up to $54 million from the sale of antipsychotic drug FazaClo, a year after acquiring the drug in anticipation of an FDA nod for Zenvia in involuntary emotional expression disorder, to move Zenvia toward the finish line in IEED and diabetic neuropathy. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription